Abstract
Aims
Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib‐related cardiotoxicity in mRCC patients.
Methods
We performed a multicenter prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6 months after cabozantinib initiation.
Results
The study population included 22 mRCC patients. At baseline, 9.1% had a reduced LVEF, but none had a LV systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3 months. After 6 months, only one had a LVEF decline > 10% compared to baseline, resulting in LV systolic dysfunction.
At baseline, 64.7% and 27.3% of patients had elevated proBNB and hsTnI, respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6 months. No correlation was found between basal elevated proBNP and basal reduced LVEF (p=0.29), and between elevated proBNP and reduced LVEF after 6 months (p=0.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF, or elevated proBPN at baseline (p=0.47; p=0.38), at 3 (p=0.059; p=0.45) and after 6 months (p=0.72; p=1.0).
Conclusions
This prospective study revealed a modest risk of developing LV systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time‐points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.
http://bit.ly/2DrxVv9
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.